|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 9190 |
FusionGeneSummary for CYSTM1_MATR3 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CYSTM1_MATR3 | Fusion gene ID: 9190 | Hgene | Tgene | Gene symbol | CYSTM1 | MATR3 | Gene ID | 84418 | 9782 |
| Gene name | cysteine rich transmembrane module containing 1 | matrin 3 | |
| Synonyms | C5orf32|ORF1-FL49 | ALS21|MPD2|VCPDM | |
| Cytomap | 5q31.3 | 5q31.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | cysteine-rich and transmembrane domain-containing protein 1UPF0467 protein C5orf32putative nuclear protein ORF1-FL49 | matrin-3vocal cord and pharyngeal weakness with distal myopathy | |
| Modification date | 20180519 | 20180519 | |
| UniProtAcc | Q9H1C7 | P43243 | |
| Ensembl transtripts involved in fusion gene | ENST00000261811, ENST00000509789, | ENST00000509990, ENST00000361059, ENST00000504203, ENST00000502929, ENST00000394800, ENST00000507197, ENST00000394805, ENST00000502499, ENST00000510056, ENST00000503811, | |
| Fusion gene scores | * DoF score | 3 X 2 X 3=18 | 4 X 4 X 3=48 |
| # samples | 3 | 4 | |
| ** MAII score | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(4/48*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CYSTM1 [Title/Abstract] AND MATR3 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | MATR3 | GO:0002218 | activation of innate immune response | 28712728 |
| Tgene | MATR3 | GO:0010608 | posttranscriptional regulation of gene expression | 21771347 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | OV | TCGA-61-1728-01A | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3CDS | ENST00000261811 | ENST00000509990 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-3CDS | ENST00000261811 | ENST00000361059 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-3CDS | ENST00000261811 | ENST00000504203 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-3CDS | ENST00000261811 | ENST00000502929 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-3CDS | ENST00000261811 | ENST00000394800 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-intron | ENST00000261811 | ENST00000507197 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-intron | ENST00000261811 | ENST00000394805 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-intron | ENST00000261811 | ENST00000502499 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-intron | ENST00000261811 | ENST00000510056 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 5UTR-intron | ENST00000261811 | ENST00000503811 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-3CDS | ENST00000509789 | ENST00000509990 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-3CDS | ENST00000509789 | ENST00000361059 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-3CDS | ENST00000509789 | ENST00000504203 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-3CDS | ENST00000509789 | ENST00000502929 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-3CDS | ENST00000509789 | ENST00000394800 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-intron | ENST00000509789 | ENST00000507197 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-intron | ENST00000509789 | ENST00000394805 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-intron | ENST00000509789 | ENST00000502499 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-intron | ENST00000509789 | ENST00000510056 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
| 3UTR-intron | ENST00000509789 | ENST00000503811 | CYSTM1 | chr5 | 139554870 | + | MATR3 | chr5 | 138654597 | + |
Top |
FusionProtFeatures for CYSTM1_MATR3 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CYSTM1 | MATR3 |
| May play a role in transcription or may interact withother nuclear matrix proteins to form the internal fibrogranularnetwork. In association with the SFPQ-NONO heteromer may play arole in nuclear retention of defective RNAs. Plays a role in theregulation of DNA virus-mediated innate immune response byassembling into the HDP-RNP complex, a complex that serves as aplatform for IRF3 phosphorylation and subsequent innate immuneresponse activation through the cGAS-STING pathway(PubMed:28712728). May bind to specific miRNA hairpins(PubMed:28431233). {ECO:0000269|PubMed:11525732,ECO:0000269|PubMed:28431233, ECO:0000269|PubMed:28712728}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for CYSTM1_MATR3 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for CYSTM1_MATR3 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| CYSTM1 | UQCR10, RAB11A, IER3IP1, NDUFB11, UQCRQ, TMX1, GNAI2, SLC16A1, GLP1R, MFSD4, SLC39A5 | MATR3 | HNRNPK, GSTK1, RUVBL2, CDK9, MEPCE, EGFR, H2AFX, UBC, CALM1, DISC1, TNFRSF21, AIMP2, SNAP23, SMARCAD1, NFX1, CUL3, CDK2, CUL1, COPS5, CAND1, NEDD8, GFI1B, PCBP1, SMU1, SAP18, STOML2, RANBP2, UTP14A, IARS2, RRP7A, PPT2, S100A9, SARS2, RRS1, NAA15, PRKCDBP, MYOF, MRPL19, MAGOH, EIF4A3, FN1, PTBP2, IFIT2, MAP1LC3A, ITGA4, PAN2, TARDBP, PARK2, RPA3, RPA2, RPA1, WWOX, ERG, LGR4, STAU1, AURKA, CEP250, MATR3, RASD1, CUL7, OBSL1, CCDC8, UBE2I, EED, SIRT6, HNRNPA1, FBXW11, UNK, NTRK1, BTF3, CALR, EEF1D, HNRNPU, ATP5A1, PUF60, RPL7, RUVBL1, SF3A3, SNRNP70, SNRPC, SRSF3, SUB1, YBX1, SRPK2, B9D2, ADAR, COPA, DDX3X, DDX5, DHX9, EWSR1, FUS, HNRNPA2B1, HNRNPC, HNRNPF, HNRNPH1, HNRNPH2, HNRNPH3, HNRNPL, ILF2, ILF3, HNRNPM, NAP1L4, NUMA1, PKP2, PPP1CA, PPP1CB, PTBP1, RBM3, RCN1, SAFB, SET, SNRPA, TAF15, PKP4, EIF3D, SRSF9, TNK1, FUBP3, APOBEC3B, SAFB2, PUM1, MPHOSPH8, HNRNPDL, PTBP3, DNAJB6, SUGP2, RBM6, ALYREF, HNRNPR, AKAP8, RBM14, DDX17, KHDRBS1, HNRNPA0, HNRNPUL1, PKP3, RALY, FAM120A, FAM208A, RBFOX2, TIMM13, AKAP8L, STAU2, RBMX, ZNF638, RBM15B, RTCB, PPHLN1, C14orf166, POLR3B, DDX28, YLPM1, NCOA5, SQRDL, ZNF106, ZNF668, SLTM, PRR3, RBM4B, GSG2, DPY30, NLRP5, ESCO2, HNRNPA3, HNRNPUL2, CXorf23, ZNF326, RBM12B, EIF2AK4, RBMXL1, CRY1, CRY2, ALKBH3, MCM5, SENP3, U2AF2, RC3H1, CRBN, ELAVL2, CDK5RAP1, CYLD, TRIM25, BRCA1, LMNA, YAP1, MTF1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for CYSTM1_MATR3 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for CYSTM1_MATR3 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CYSTM1 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | MATR3 | C3807521 | AMYOTROPHIC LATERAL SCLEROSIS 21 | 2 | ORPHANET;UNIPROT |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|